Dendritic cells (DCs) play a crucial role in maintaining the immune system. Although DC-based cancer immunotherapy has been suggested as a potential treatment for various kinds of malignancies, clinical e‹cacies have been still unsatisfactory. To improve the clinical outcome of DC-based cancer immunotherapy, we are now focusing on 1) increase of numbers of therapeutic immune cells, i.e., DCs, and 2) the development of new methods for stimulating them. We have recently established a possible breakthrough, a simple cytokine-based culture method to realize a log-scale order of functional myeloid-type murine/human DCs. Moreover, we demonstrated that DCs activated by replication-deˆcient recombinant Sendai virus (rSeV) were highly eŠective than that seen in the use of current DC vaccine stimulated by conventional cytokines etc., for immunotherapy against malignancies. Therefore, our study strongly suggests that these improvements could overcome the current limitations of DC-based immunotherapy for malignancies.
DCs may be prepared ex vivo following 3 general methods (lower left), each of which results in a diŠerent mixture of cells. DCs may be matured and loaded with antigens using a variety of techniques. Some of these techniques include the addition of DC survival factors, the use of substances that induce cross-presentation, or the use of stimulators of other innate immune cells such as NKT cells. DCs loaded with RNA or DNA can take advantage of sequences encoding cytokines, chemokines, or DC survival factors. Numerous variables such as antigen dose, cell dose, and route of administration also need to be optimized. In addition, less costly and labor-intensive approaches that stimulate and load DCs with antigen in situ are being explored. There are many unresolved issues regarding the monitoring of immune responses and in correlating these responses with clinical outcome. DC vaccines may prove to be most eŠective in the adjuvant setting or in combination with other treatments. Thisˆgure is adapted from Ref. 1. 
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. Timing of Administration of DC is Critical to Optimize the Prevention of Lung Metastasis and Determination of EŠector Cell Subsets for Preventing Lung Metastasis
A: Treatment regimen. DCs, 10 6 cells of immature DC (iDC) or rSeV/dF-GFP/DC, were i.v. administered via the tail vein at day -28, -14, -7, or -2. On day 0, 10 5 RM-9 tumor cells were inoculated i.v. Twenty-one days later, the animals were sacriˆced and the numbers of metastatic nodules on the pleural surface of bilateral lungs were evaluated macroscopically. B: Timing of administration of DC-rSeV/dF-therapy is critical to optimize the prevention of lung metastasis of RM-9 prostate cancer. The number of metastatic nodules of each group is given. C: EŠects of eŠector cell depletion (for NK cells: rabbit anti-asialoGM1 polyclonal Ab＝ anti-AGM1, for CD4 ＋ T-lymphocytes: anti-CD4 mAb from hybridoma GK1.5＝anti-CD4, and for CD8 ＋ T-lymphocytes: anti-CD8 mAb from hybridoma TIB105 ＝anti-CD8) for the prevention of lung metastasis of RM-9. Anti-asialo GM1 was given i.p. (100 mg/dose) for NK cell depletion on days -8, -6, -4, 0, and 3 after tumor inoculation. CD4 ＋ or CD8 ＋ cells in the mice were eliminated by i.p. injection of mAbs on days -8, -6, -4, 0, and every 3 or 4 days until sacriˆce after tumor inoculation. FACS analyses conˆrmed ＞98％ depletion of the target cells in peripheral blood from the tail vein for at least 7 days after injection in animals. Treatment with aAGM1 dramatically increased the number of metastatic nodules. Note that both mAbs, anti-CD4 and anti-CD8, signiˆcantly impaired the preventive eŠect of DC-rSeV/dF-mediated antimetastatic activity, and anti-CD4 showed a more pronounced eŠect ( p＜0.01) than that seen with anti-CD8 ( p＜0.05). D: Another set from the same experiment as c assessing long-term survival. The survival curve was determined using the Kaplan-Meier method, and the log-rank test was used to compare curves among groups. Treatment with anti-AGM1 on days -8, -6, -4, 0, and 3 signiˆcantly accelerated death, even though DC-rSeV/dF was given 28 days before tumor inoculation ( p＜0.01). Administration of anti-CD8 did not impair the survival of DC-rSeV/dF-treated mice; in contrast, injection of anti-CD4 almost completely abolished the eŠect of DC-rSeV/dF ( p＜0.01). These A Dˆgures are adopted from Ref. 12 Seven days after subcutaneous c1300 tumor inoculation into the left thigh, the tumors were irradiated 3 times daily at 4 Gy/day. At day 10, 10 6 cells of ts-rSeV/ dF-DCs with exogenous mIFN-b expression were injected weekly via the intratumoral route. Four animals with completely eliminated tumors via overdose irradiation (34 Gy×3 for 3 days) were also included. On day 184, live animals without primary tumor formation were subjected to a second challenge, simultaneous tumor inoculation with c1300 and MuSS (third party) on the abdominal wall. Fifteen days later, tumor formation was determined. Theˆgure is adopted from Ref. 6 
